Transgene shares surge 20% on positive Phase 1 cancer vaccine data

Transgene reported positive results from the first phase of clinical trials for its cancer vaccine, triggering a 20% jump in its stock. The data are early-stage and unquantified in the report, so efficacy and safety remain uncertain. The market reaction signals investor optimism for the company's pipeline, though broader implications are limited until later-stage results.